← Back to patent-cliff list
Copper (64Cu) oxodotreotide
Tier C — Watch / tradeCopper (64Cu) oxodotreotide
Radiomedix Inc
Originator
2020
First approval
-
Expiry (public)
No sales data
Peak sales
In vivo diagnostic
Type
Targets：SSTR
Brand：Detectnet
Indications (approved)：Neuroendocrine tumour
Regional status
US
Approved
2020-09-03
EU
-
China
Phase III
2026-03-22
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Copper (64Cu) oxodotreotide?
Approved indications include: Neuroendocrine tumour.
When does the Copper (64Cu) oxodotreotide patent expire?
No public expiry year is available for Copper (64Cu) oxodotreotide yet; this page updates once verified.
How do I get a quote for Copper (64Cu) oxodotreotide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27